Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook

Core Insights - Ionis Pharmaceuticals reported a narrower adjusted loss per share of $1.14 for Q4 2025, compared to the Zacks Consensus Estimate of a loss of $1.21, and an adjusted loss of 43 cents in the same period last year [1] - Total revenues for the quarter were $203 million, exceeding the Zacks Consensus Estimate of approximately $156 million, but reflecting a 10.6% decline year over year [2] Revenue Breakdown - The company has two wholly-owned marketed drugs: Tryngolza for familial chylomicronemia syndrome (FCS) and Dawnzera for hereditary angioedema, with Tryngolza launched in the U.S. in 2024 and Dawnzera approved in the EU in January 2026 [3] - Ionis has five partnered marketed drugs, including Spinraza and Qalsody in partnership with Biogen, and Wainua with AstraZeneca, generating royalties and distribution fees [4] Commercial Performance - Commercial revenues surged 64% year over year to $141 million, driven by Tryngolza's sales of $50 million, which increased by 56% year over year, and Dawnzera's $7 million in its first full quarter [5] - Spinraza royalties totaled $54 million, down 15.6% year over year, while Wainua royalties increased to $16 million from $10 million in the previous quarter [6] R&D and Costs - R&D revenues fell 56% year over year to $62 million but exceeded the Zacks Consensus Estimate of $25 million [7] - Adjusted operating costs rose 24.6% year over year to $375 million, with SG&A costs increasing by 52% to support commercialization efforts [9] Full-Year Results and Guidance - For 2025, total revenues reached $944 million, up 34% year over year, surpassing guidance, but included a one-time payment from Ono Pharmaceutical [10] - The company issued guidance for 2026, expecting revenues between $800 million and $825 million, which is below the Zacks Consensus Estimate of $867.3 million [11] Market Sentiment - The soft 2026 guidance led to a 5% decline in shares despite better-than-expected Q4 results, with concerns over slower product sales uptake for Tryngolza and Dawnzera [12] - Over the past year, Ionis shares have increased by 158.2%, significantly outperforming the industry growth of 3.5% [14] Pipeline Updates - Ionis is developing Tryngolza for severely elevated triglycerides (sHTG), with positive results from phase III studies, and has submitted a supplemental new drug application for expanded use [17] - Other candidates in the pipeline include zilganersen for Alexander disease and obudanersen for Angelman syndrome, with expected data releases in 2026 and 2027 respectively [19] Partnered Drug Developments - Ionis and AstraZeneca are developing Wainua for cardiomyopathy caused by hereditary TTR amyloidosis, with data expected in the second half of 2026 [20] - Bepirovirsen, developed in partnership with GSK for chronic hepatitis B, has shown positive phase III results, with regulatory filings anticipated in Q1 2026 [22]